Adicet Bio (ACET) Financials

Adicet Bio (NASDAQ: ACET) remains a development-stage biotechnology company with no reported revenue in the periods provided. Its financial profile continues to be defined by recurring research spending, operating losses and cash consumption, although the company maintains a relatively strong balance sheet with more liquid assets than liabilities.

• Substantial liquidity remains: As of June 30, 2026, Adicet reported $33.1 million in cash and equivalents and $85.1 million in short-term investments, or approximately $118.2 million of cash and marketable investments. This compares with $137.6 million at March 31, 2026.
• Balance-sheet leverage is low: Total liabilities were $28.0 million versus $120.1 million of equity. Current assets of $120.8 million were approximately 6.7 times current liabilities of $18.0 million, providing a sizable liquidity cushion relative to near-term obligations.
• Quarterly cash burn improved modestly: Net cash used in operating activities declined to $19.8 million in Q2 2026 from $21.5 million in Q1 2026 and $26.6 million in Q2 2025. The Q2 2026 net loss of $21.4 million also improved from the $30.5 million loss reported in Q4 2025.
• Investment income helps offset expenses: Interest and investment income contributed $1.2 million in Q2 2026. Although this is not an operating revenue stream, the company’s cash and investment balances continue to generate a partial offset to its research and administrative costs.
• Investment portfolio activity drove reported investing cash flow: Adicet generated $16.7 million of investing cash flow in Q2 2026 after $41.0 million of investments matured or were sold and $24.1 million were purchased. This primarily reflects portfolio management rather than internally generated cash.
• Capital spending is limited: Purchases of property and equipment were only $0.2 million in Q2 2026, suggesting that the company’s cash needs are driven overwhelmingly by research and development rather than heavy capital investment.
• Adicet has not yet established commercial revenue: Reported revenue was $0 in each of the disclosed income-statement periods. Consequently, the company remains dependent on its cash resources, investment income and future financing or strategic transactions.
• Operating losses remain substantial and persistent: Q2 2026 operating expenses totaled $22.3 million, including $18.5 million of research and development expense. Net losses have generally remained near or above $20 million per quarter since 2023, with retained earnings reaching a deficit of $656.3 million by June 30, 2026.
• Research spending increased sequentially: R&D expense rose to $18.5 million in Q2 2026 from $17.5 million in Q1 2026, even as SG&A declined to $3.9 million from $4.1 million. Higher research spending could accelerate pipeline development, but it also increases near-term cash consumption.
• Future dilution remains a key risk: Adicet raised approximately $75.2 million through common-equity issuance in Q4 2025. The common-stock balance increased from $680.6 million in Q3 2024 to $776.5 million in Q2 2026, while the reported share count has varied significantly because of financings and restatements. Additional capital raises could dilute existing shareholders if operating cash flow does not improve.

At the Q2 2026 operating burn rate, the company’s approximately $118 million of cash and short-term investments represent roughly five to six quarters of liquidity before considering changes in investment income, clinical spending, milestone payments, financing activity or working capital. This is only a rough comparison, not a forecast, and the cash runway could change materially as clinical programs advance.

Overall, ACET’s financial statements show a company with a comparatively low-debt balance sheet and meaningful liquidity, but no revenue base and continuing dependence on external capital. The most important factors for investors are whether Adicet can convert its research investments into clinical or commercial milestones, maintain its cash runway and limit the need for additional dilutive financing. Comparisons should also be made cautiously because several 2024 and 2025 statements in the supplied data were marked as restated.